Dr Lai qualified in medicine and underwent training in internal medicine, followed by specialization in oncology. Dr Lai was later responsible for clinical research programs of novel signal disrupting agents for solid tumors and hematological malignancies at a global pharmaceutical company. He has extensive experience in the process of drug development, from phase 1 dose-escalation studies to large-scale, phase 3 randomized controlled trials and post-marketing surveys. In addition, he is also experienced in regulatory and health economic issues related to pharmaceutical products. Dr Lai is an experienced editor and began editing for the Edanz Group in 2010.